Ron Martell

Insider Reports History

Location
Poniard Pharmaceuticals, Inc., 750 Battery Street, Suite 330, San Francisco, CA
Signature
/s/ Herb Cross, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Ron Martell:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Jasper Therapeutics, Inc. President and CEO, Director Voting Common Stock 74.1K $180K $2.43 Sep 22, 2025 Direct
Jasper Therapeutics, Inc. President and CEO, Director Stock Option (right to buy) 234K Jun 4, 2025 Direct
Jasper Therapeutics, Inc. President and CEO, Director Common Stock Warrant (right to buy) 41K Sep 22, 2025 Direct

Insider Reports Filed by Ron Martell

Symbol Company Period Transactions Value $ Form Type Date Filed Role
JSPR Jasper Therapeutics, Inc. Sep 22, 2025 2 $99.6K 4 Sep 24, 2025 President and CEO, Director
JSPR Jasper Therapeutics, Inc. Jun 4, 2025 1 $0 4 Jun 6, 2025 President and CEO, Director
JSPR Jasper Therapeutics, Inc. Feb 13, 2025 1 $0 4 Feb 18, 2025 President, CEO and Director, Director
JSPR Jasper Therapeutics, Inc. Jun 10, 2024 2 $0 4 Jun 12, 2024 President, CEO and Director, Director
JSPR Jasper Therapeutics, Inc. Feb 15, 2024 1 $0 4 Feb 20, 2024 President, CEO and Director, Director
JSPR Jasper Therapeutics, Inc. Oct 12, 2023 1 -$74.4K 4 Oct 13, 2023 President, CEO & Director, Director
JSPR Jasper Therapeutics, Inc. Apr 12, 2023 1 -$128K 4 Apr 14, 2023 President, CEO and Director, Director
JSPR Jasper Therapeutics, Inc. Mar 17, 2023 1 $0 4 Mar 20, 2023 President, CEO and Director, Director
JSPR Jasper Therapeutics, Inc. Feb 2, 2023 1 $0 4 Feb 3, 2023 President, CEO & Director, Director
JSPR Jasper Therapeutics, Inc. Oct 12, 2022 1 $0 4 Oct 13, 2022 President, CEO and Director, Director
JSPR Jasper Therapeutics, Inc. Mar 21, 2022 1 $0 4 Mar 23, 2022 President, CEO and Director, Director
JSPR Jasper Therapeutics, Inc. Mar 15, 2022 0 $0 3 Mar 21, 2022 President, CEO and Director, Director